Biora Therapeutics Ownership
| BIOR Stock | USD 1.93 0.14 7.82% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 74.2 B | Current Value 3.7 M | Avarage Shares Outstanding 3.2 B | Quarterly Volatility 15.5 B |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Biora |
Biora Stock Ownership Analysis
About 29.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. Biora Therapeutics had 1:10 split on the 18th of October 2024. Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. Biora Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. For more info on Biora Therapeutics please contact Aditya MBA at 833 727 2841 or go to https://www.bioratherapeutics.com.Besides selling stocks to institutional investors, Biora Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Biora Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Biora Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Biora Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Biora Therapeutics are currently held by insiders. Unlike Biora Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Biora Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Biora Therapeutics' insider trades
Biora Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biora Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biora Therapeutics backward and forwards among themselves. Biora Therapeutics' institutional investor refers to the entity that pools money to purchase Biora Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Barclays Plc | 2024-06-30 | 5.8 K | Wells Fargo & Co | 2024-06-30 | 4.1 K | Efficient Wealth Management Llc | 2024-09-30 | 1.5 K | Td Waterhouse Canada Inc | 2024-06-30 | 1.1 K | Advisor Group Holdings, Inc. | 2024-06-30 | 647 | Riggs Asset Management Co Inc | 2024-06-30 | 400 | Bank Of America Corp | 2024-06-30 | 179 | Hartland & Co | 2024-06-30 | 144 | Royal Bank Of Canada | 2024-06-30 | 74.0 | Athyrium Capital Management Lp | 2024-06-30 | 10.9 M | Vanguard Group Inc | 2024-06-30 | 697.3 K |
Biora Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biora Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biora Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biora Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biora Therapeutics Outstanding Bonds
Biora Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biora Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biora bonds can be classified according to their maturity, which is the date when Biora Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US74319RAA95 Corp BondUS74319RAA95 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Pair Trading with Biora Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biora Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biora Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Biora Stock
| 0.81 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.87 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.95 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Biora Stock
| 0.91 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.81 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.62 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.6 | PHVS | Pharvaris BV | PairCorr |
| 0.4 | ESLAW | Estrella Immunopharma | PairCorr |
The ability to find closely correlated positions to Biora Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biora Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biora Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biora Therapeutics to buy it.
The correlation of Biora Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biora Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biora Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biora Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Biora Stock Analysis
When running Biora Therapeutics' price analysis, check to measure Biora Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biora Therapeutics is operating at the current time. Most of Biora Therapeutics' value examination focuses on studying past and present price action to predict the probability of Biora Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biora Therapeutics' price. Additionally, you may evaluate how the addition of Biora Therapeutics to your portfolios can decrease your overall portfolio volatility.